TSE:MDNA Medicenna Therapeutics (MDNA) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free MDNA Stock Alerts C$2.49 +0.54 (+27.69%) (As of 04/26/2024 ET) Add Compare Share Share Today's RangeC$2.09▼C$2.6250-Day RangeC$0.96▼C$1.9652-Week RangeC$0.22▼C$2.62Volume738,582 shsAverage Volume135,659 shsMarket CapitalizationC$173.40 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Medicenna Therapeutics alerts: Email Address Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Medicenna Therapeutics Stock (TSE:MDNA)Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Read More MDNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MDNA Stock News HeadlinesApril 26, 2024 | ca.finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - MDNAApril 26, 2024 | finance.yahoo.comMedicenna Therapeutics Announces CA$20 Million Investment from RA Capital ManagementApril 27, 2024 | WealthPress (Ad)It’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. April 26, 2024 | americanbankingnews.comMedicenna Therapeutics (TSE:MDNA) Trading 12.9% Higher April 9, 2024 | finance.yahoo.comMedicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)April 9, 2024 | finance.yahoo.comMedicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)March 27, 2024 | theglobeandmail.comMedicenna Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (MDNA)March 6, 2024 | finance.yahoo.comMedicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual MeetingApril 27, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 13, 2024 | finance.yahoo.comMedicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsJanuary 9, 2024 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabJanuary 9, 2024 | finance.yahoo.comMedicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with PembrolizumabNovember 20, 2023 | finance.yahoo.comAll You Need to Know About Medicenna Therapeutics Corp. (MDNAF) Rating Upgrade to BuyNovember 14, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational HighlightsNovember 9, 2023 | finance.yahoo.comMedicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingOctober 24, 2023 | tmcnet.comMedicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)October 24, 2023 | finance.yahoo.comMedicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)October 10, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerOctober 5, 2023 | nasdaq.comMedicenna Therapeutics (MDNA) Price Target Increased by 34.63% to 3.93October 3, 2023 | finance.yahoo.comMedicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and ImmunotherapySeptember 29, 2023 | finanznachrichten.deMedicenna Therapeutics Corp.: Medicenna Announces Results of Annual and Special Meeting of ShareholdersSeptember 28, 2023 | finance.yahoo.comMedicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and ImmunotherapySeptember 26, 2023 | finance.yahoo.comIs Medicenna Therapeutics (TSE:MDNA) In A Good Position To Invest In Growth?September 6, 2023 | finance.yahoo.comMedicenna to Participate at The H.C. Wainwright 25th Annual Global Investment ConferenceAugust 28, 2023 | msn.comMedicenna Therapeutics gets new CFOAugust 28, 2023 | finance.yahoo.comMedicenna Announces the Appointment of Jeff Caravella as Chief Financial OfficerAugust 24, 2023 | theglobeandmail.comClosing Bell: Medicenna Therapeutics Corp up on Wednesday (MDNA)See More Headlines Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/27/2024Next Earnings (Estimated)6/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:MDNA CUSIPN/A CIKN/A Webwww.medicenna.com Phone+1-403-6807898FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-15,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.47% Return on Assets-34.57% Debt Debt-to-Equity Ratio0.06 Current Ratio5.00 Quick Ratio4.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$2.17 per share Price / Cash Flow1.15 Book ValueC$0.27 per share Price / Book9.22Miscellaneous Outstanding Shares69,640,000Free FloatN/AMarket CapC$173.40 million OptionableNot Optionable Beta1.16 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Fahar Merchant Ph.D. (Age 67)Founder, Chairman, President & CEO Comp: $454.37kMs. Rosemina Merchant B.Sc. (Age 67)M.E.Sc, Founder & Chief Development Officer Comp: $364.46kMr. David Hyman CA (Age 51)CBV, Chief Financial Officer Dr. Samuel R. Denmeade M.D.Scientific AdvisorKey CompetitorsOncolytics BiotechTSE:ONCScythian BiosciencesCVE:SCYB138267 (COM.TO)TSE:COMNovoheartCVE:NVHIntelGenx TechnologiesCVE:IGXView All Competitors MDNA Stock Analysis - Frequently Asked Questions How have MDNA shares performed in 2024? Medicenna Therapeutics' stock was trading at C$0.42 at the beginning of the year. Since then, MDNA stock has increased by 492.9% and is now trading at C$2.49. View the best growth stocks for 2024 here. When is Medicenna Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 25th 2024. View our MDNA earnings forecast. What other stocks do shareholders of Medicenna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medicenna Therapeutics investors own include OPKO Health (OPK), AbbVie (ABBV), Livongo Health (LVGO), Aptose Biosciences (APTO), Birchcliff Energy (BIR), CVS Health (CVS), Freehold Royalties (FRU), Fastly (FSLY) and Inovio Pharmaceuticals (INO). How do I buy shares of Medicenna Therapeutics? Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:MDNA) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss RatingsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.